Research Notes

ARM & HAMMER

CELMANAX helped improve health and performance in preweaned commercial dairy calves

STUDY OVERVIEW

- Optimizing health and reducing morbidity and mortality in preweaned dairy calves without antibiotics is of primary interest.
- This trial¹ was conducted to evaluate health and performance of milk-fed commercial Holstein calves supplemented with CELMANAX.[™]
- The study was conducted at two commercial farms in Wisconsin (Herd A, n = 120 (38%); Herd B, n = 199 (62%)). Calves were housed indoors, individually, for days 1 6, and then group housed with an automatic feeder until day 56. Three-day-old calves were randomized into treatments with about 80 calves per treatment.
- The study included the following dietary treatments:
 - Control
 - CELMANAX SCP 2g/h/d
- Calves were monitored for overall health, fecal pathogen shedding, and average daily gain (ADG) during the preweaning period.
- Data was statistically analyzed for overall means and to account for variables including treatment, farm, study week and month, and passive transfer status.

RESULTS

- Besides treatment interactions, interactions were also noted between farm origin, study week, study month and passive transfer status. However, the following overall conclusions were noted.
- CELMANAX numerically reduced predicted probability of severe diarrhea (Figure 1).
- CELMANAX reduced prevalence of *Salmonella* (*P*=0.03) and rotavirus (*P*=0.03) but did not change the prevalence of *C. parvum* and coronavirus (Figure 2).







• CELMANAX[™]-fed calves had numerically higher body weight gain at 48 days of age compared to control calves (Figure 3).

CONCLUSIONS

- CELMANAX helped improve some gut health parameters, which led to numerical improvement of growth and performance in preweaned dairy calves.
- It appears that the ability of CELMANAX to protect young dairy calves from developing severe diarrhea likely depends on herd levels factors.



NOTE: The study presented here was part of a larger study where CELMANAX SCP Og, 1g, 2g and 4g were tested. 2g inclusion gave the best overall results.





1 The complete study has been presented at AABP, September 14-16, 2017, Omaha, Nebraska. © 2019 Church & Dwight Co., Inc. ARM & HAMMER, the ARM & HAMMER logo and CELMANAX are trademarks of Church & Dwight Co., Inc. CE3343-0719